Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion

发生了什么

The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones

摘要按规则整理自下方来源原文

来源